Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform General Information

Description

Rights of an allogeneic, non-viral chimeric antigen receptor (CAR) technology platform. Non-viral chimeric antigen receptor (CAR) technology platform which leverages Cytokine-Induced Killer (C.I.K.) cells as immune effector cells, is developed at University of Milano-Bicocca.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Healthcare Technology Systems
Primary Office
  • Piazza dell'Ateneo Nuovo, 1
  • 20126 Milan
  • Italy
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform‘s full profile, request access.

Request a free trial

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform‘s full profile, request access.

Request a free trial